Key result
Women and elderly patients with ischaemic heart disease were less likely to receive secondary preventive therapies like beta-blockers.
Why the study?
Does female gender or older age reduce the likelihood of receiving secondary preventive therapies in patients with ischaemic heart disease?
Does female gender or older age reduce the likelihood of receiving secondary preventive therapies in patients with ischaemic heart disease?
Answers are grounded in this paper and cite their sources.
Women and elderly patients with ischemic heart disease are significantly less likely to be prescribed evidence-based secondary preventive therapies in primary care.
AIMS: To determine if a gender or age bias exists in the prescription of important secondary preventive therapies for ischaemic heart disease in primary care. METHODS: We identified 15 590 patients with ischaemic heart disease on the basis that they received a prescription for nitrate therapy over a 1-year period (September 1999 to August 2000) from the Eastern Region of the General Medical Services scheme in Ireland (population of 334 031), which provides free health service to those eligible patients in primary care. Odds ratios (OR) for the prescription of aspirin, beta-blockers, statins, calcium channel antagonists and ACE inhibitors in women and in those aged> 65 years were determined. RESULTS: Female patients were less likely to receive a prescription for a beta-blocker [OR = 0.84, 95% confidence interval (CI) = 0.79, 0.89, P < 0.001], aspirin (OR = 0.72, 95% CI = 0.67, 0.78, P < 0.001), and ACE inhibitors (OR = 0.83, 95% CI = 0.78, 0.89, P < 0.001) compared with their male counterparts. However, women were more likely to receive anxiolytic benzodiazepines (OR = 1.71, 95% CI = 1.59, 1.85, P < 0.001) compared with their male counterparts. Elderly patients (aged> 65 years) were less likely to receive aspirin (OR = 0.92, 95% CI = 0.85, 0.99, P < 0.001), beta-blocker (OR = 0.66, 95% CI = 0.62, 0.71, P < 0.001) and a statin (OR = 0.5, 95% CI = 0.46, 0.53, P < 0.001). CONCLUSIONS: An age and gender bias exists in the prescription of important secondary preventive therapies in primary care that may lead to increased mortality from ischaemic heart disease in these groups.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2003) studied this question. Women and elderly patients with ischaemic heart disease were less likely to receive secondary preventive therapies like beta-blockers.
Synapse has enriched 10 related papers. Consider them for comparative context: